Search Results

MC# 21-41
A Phase I Study of ASP1570 in Participants with Advanced Solid Tumors

MC# 21-44
A Phase I Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients with Advanced Solid Tumors

MC# 22-02
A First-in-Human, Phase I/II, Open-Label, Multi-Center, Dose-Escalation and Dose-Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination with PARP Inhibitor Senaparib in Patients with Advanced Solid Tumors

MC# 22-08
A First-in-Human, Multicenter, Phase I/II, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors

MC# 22-12
A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants with Advanced Solid Tumors

MC# 22-13
A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants with Advanced Solid Tumors

MC# 22-14
A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

MC# 22-20
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

MC# 22-29
A Phase I, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors

MC# 18-26
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

MC# 20-15
A Phase I First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors

MC# 21-17
A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

MC# 21-36
An Open-Label, Multicenter, Phase I Study Of IGM-8444 as a Single Agent and in Combination in Subjects with Relapsed and/or Refractory Solid Cancers

MC# 21-39
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Retifanlimab and Epacadostat

MC# 22-28
A Phase I Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

MC# 19-25
A Phase Ib Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects with Previously Treated Advanced HER2-positive Solid Tumors

MC# 22-09
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

MC# 22-31
A Phase I Trial of SIM1811-03 in Subjects with Advanced Solid Tumors and Cutaneous T-cell Lymphoma

MC# 19-37
Subprotocol L: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with BI 1701963 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation

MC# 20-08
An Open-label, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

MC# 21-07
An Open-Label, Multi-Center Phase I/Ib Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors

MC# 21-10
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as a Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

MC# 21-14
A Phase I, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of the WEE1 Inhibitor IMP7068 Monotherapy in Patients with Advanced Solid Tumors

MC# 21-43
A Phase Ia/Ib, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies followed by an Expansion Part with Triplet Combinations of S095029 and Sym021 and an Anti-HER2 mAb or Anti-EGFR mAbs (futuximab/modotuximab) in Patients with Metastatic Gastric or Colorectal Cancers

MC# 22-05
A Phase I Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1